Targets › HGNC
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: the race on HGNC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals | INO-5401 DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens | WT1, PSMA, HGNC | Phase 1 | Glioblastoma | Dec 2027 |
Glioblastoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.